Press monitoring
Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
10.3.2016 | Press monitoring
Oslo 10 March 2016 - Targovax has conducted a predetermined interim analysis of the TG01 Phase I/II trial, indicating promising 1-year overall survival data when combining TG01 with gemcitabine (chemotherapy) as supplementary treatment of patients with pancreatic cancer.
First European Patients Enroll in Medtronic International Lung Cancer Study
10.3.2016 | Press monitoring
DUBLIN - March 10, 2016 - Committed to technologies that assist in the goal of reducing lung cancer morbidity worldwide, Medtronic (NYSE: MDT) today announced European enrollment in the NAVIGATE clinical trial. This 2,500-patient international study will assess the long-term impact of its superDimension(TM) navigation system as an aid in early...
Researchers report cell-to-cell movement of mitochondria through a graft junction
9.3.2016 | Press monitoring
A team of researchers with Rutgers University has found an example via experimentation, of cell-to-cell movement of mitochondria through a graft junction of two tobacco species. In their paper published in PNAS, the team describes their experiments with grafting tobacco plants and what they learned about cells swapping mitochondria during the...
Growth of functional breast tissue spawns a new weapon in cancer research
7.3.2016 | Press monitoring
Current approaches to breast cancer research have their limitations when it comes to observing its behavior in live human tissue. There is something to be gained by studying cells in mice and the lab, but these methods still don't paint a complete picture. Researchers have now built a hydrogel scaffold that mimics the environment found within...
Supercomputer probes depths of biofuel\'s biggest barrier
4.3.2016 | Press monitoring
Ask a biofuel researcher to name the single greatest technical barrier to cost-effective ethanol, and you're likely to receive a one-word response: lignin. Cellulosic ethanol—fuel derived from woody plants and waste biomass—has the potential to become an affordable, renewable transportation fuel that rivals gasoline, but lignin, one of the most...
Glow-in-the-dark bacterial lights could illuminate shop windows
2.3.2016 | Press monitoring
Bacteria may light up the future. Glowee, a start-up company based in Paris, France, is developing bioluminescent lights to illuminate shop fronts and street signs. After a successful demo in December, Glowee has launched its first product – a bacteria-powered light that glows for three days. The company is now working on lights that will glow...
Actelion emphasizes commitment to advance research and care in rare diseases
29.2.2016 | Press monitoring
ALLSCHWIL, SWITZERLAND - 29 February 2016 - Today, on Rare Disease Day 2016, patients, their families and caregivers, patient organizations, medical professionals, politicians and researchers are coming together to raise awareness for what living with a rare disease means for those affected and for their families.
Summit Therapeutics Supports Ninth Annual Rare Disease Day
29.2.2016 | Press monitoring
Oxford, UK, 29 February 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces today its support for the ninth annual Rare Disease Day on 29 February 2016. The Rare Disease Day 2016 theme,...
LivaNova PLC Receives Regulatory Approval in Japan for the Solo Smart Stentless Tissue Aortic Valve
29.2.2016 | Press monitoring
LONDON, Feb. 29, 2016 (GLOBE NEWSWIRE) -- LivaNova, PLC (NASDAQ:LIVN) (LSE:LIVN), a global medical technology company and a leader in the treatment of cardiovascular diseases, today announced that it has received approval from Japan's Pharmaceutical and Medical Devices Agency (PMDA) for its Solo Smart stentless tissue valve, the only valve...
Ordinary skin cells turned into brain tumor predators
29.2.2016 | Press monitoring
The 2006 discovery that mature skin cells can be converted into stem cells opened up exciting possibilities in regenerative medicine. Team from the University of North Carolina at Chapel Hill (UNC) has built on this technology to transform adult skin cells into cancer-killing stem cells that seek and destroy brain tumors. Glioblastomas are the...
